RESUMEN
PURPOSE: To determine whether ebselen has a protective effect or antioxidative potential in a sodium-selenite-induced experimental cataract model. SETTING: Firat University, Elazig, Turkey. DESIGN: Experimental study. METHODS: Twenty-one Sprague-Dawley rat pups were randomly divided into a control group, a sodium-selenite-induced-cataract group, and an ebselen-treated group; each group contained 7 rat pups. Rats in the control group received dimethyl sulfoxide (DMSO) intraperitoneally only and rats in the sodium-selenite-induced-cataract group received 30 nmol/g body weight sodium selenite subcutaneously and DMSO intraperitoneally 10 days postpartum. Rats in the ebselen group received 30 nmol/g body weight sodium selenite subcutaneously 10 days postpartum and were treated with 5 mg/kg body weight ebselen once a day for 4 consecutive days. Cataract development was assessed weekly for 3 weeks by slitlamp examination and graded using a scale. Reduced glutathione (GSH), total nitrite, and malondialdehyde (MDA) levels in lens supernatants were measured at the end of 3 weeks. RESULTS: In the control group, all lenses were clear. In the ebselen-treated group, the mean cataract stage was significantly lower than in the sodium-selenite-induced-cataract group (P = .022). The GSH levels were significantly lower in the sodium-selenite-induced-cataract group than in the control and ebselen groups (P < .001). The MDA levels were lower in the ebselen group than in the sodium-selenite-induced-cataract group (P < .001). The mean total nitrite level was significantly lower in the sodium-selenite-induced-cataract group than in the ebselen group (P = .001). CONCLUSIONS: Ebselen had a protective effect on cataract development in a sodium-selenite-induced experimental model. The protective effect of ebselen appears to be due to inhibition of oxidative stress. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Asunto(s)
Antioxidantes/uso terapéutico , Azoles/uso terapéutico , Catarata/prevención & control , Modelos Animales de Enfermedad , Cristalino/efectos de los fármacos , Compuestos de Organoselenio/uso terapéutico , Animales , Catarata/inducido químicamente , Catarata/metabolismo , Catarata/patología , Glutatión/metabolismo , Isoindoles , Cristalino/metabolismo , Malondialdehído/metabolismo , Nitritos/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Selenito de Sodio/toxicidadRESUMEN
PURPOSE: To describe a central retinal artery occlusion in a patient with antineutrophil cytoplasmic antibody (ANCA) negative Churg-Strauss syndrome. METHODS: Review of clinical and laboratory findings of a 44-year-old woman with ANCA negative Churg-Strauss syndrome that developed sudden vision loss in left eye. RESULTS: Left central retinal artery occlusion was diagnosed by retinal whitening, a cherry-red spot, and delayed arterial filling on fluorescein angiography. Perinuclear ANCA and cytoplasmic ANCA were negative. CONCLUSION: Central retinal artery occlusion can occur in ANCA negative Churg-Strauss syndrome. Patients with this diagnosis should be considered for prophylactic high dose corticosteroid, regardless of their ANCA status.